Introduction

Biotech Statistics: The biotechnology sector has experienced significant growth, underscored by substantial market valuations and investment activities. In 2023, the global biotechnology market was valued at approximately USD 1.55 trillion and is projected to expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. This growth trajectory suggests a market size of around USD 3.88 trillion by 2030.

The United States biotechnology market, specifically, was valued at USD 552.43 billion in 2023 and is anticipated to reach approximately USD 1.79 trillion by 2033, reflecting a CAGR of 12.45% from 2024 to 2033. In 2023, the combined biotechnology industries of the U.S. and Europe secured approximately USD 81.1 billion in capital, encompassing venture capital, initial public offerings (IPOs), follow-on offerings, and debt financing. This robust investment landscape has been instrumental in driving innovation and development within the sector.

These statistics highlight the biotechnology industry's dynamic expansion and its pivotal role in advancing medical and technological innovations globally.

In 2022, there were ***** companies performing research and development activities in biotechnology in Spain. Out of the total, *** companies were conducting biotech-related activities as their exclusive business activity, while *** firms carried out biotechnology activities as a necessary tool for production. As of that date, most Spanish companies and organizations undertaking R&D activities in biotechnology focused on bioprocesses.

Introduction

Industrial Biotechnology Statistics: Industrial biotechnology is changing industries with inventions that lower environmental impacts, make processes efficient, and make alternatives sustainable. Biotechnology can apply biological systems and even living organisms, whose applications are used in various industries, such as agriculture, environmental management, and healthcare. Majoring in this field becomes important for sustainable solution development and medical innovations.

Biopharmaceuticals, genetic engineering, bioinformatics, and other pieces of synthetic biology are involved in this industry. The following is a detailed study of industrial biotechnology statistics in the year 2024, including growth trends, market valuation, and prospects.

Table of INEBase Business Sector Biotechnology indicators by relevance of biotechnology to company activity. National. Statistics on Biotechnology Use

The Life Sciences Analytics market is experiencing robust growth, projected to reach $10.25 billion in 2025 and exhibiting a Compound Annual Growth Rate (CAGR) of 12.02% from 2025 to 2033. This expansion is fueled by several key drivers. The increasing volume and complexity of data generated within the pharmaceutical and biotechnology sectors necessitates advanced analytics solutions for efficient drug discovery, clinical trials management, regulatory compliance, and personalized medicine initiatives. Furthermore, the growing adoption of cloud-based solutions offers scalability, cost-effectiveness, and enhanced data accessibility, significantly contributing to market growth. The market is segmented by deployment (cloud and on-premises) and end-user (pharmaceutical companies, biotechnology companies, and others). Cloud deployment is expected to dominate due to its inherent advantages. North America currently holds the largest market share, driven by substantial investments in R&D and the presence of major pharmaceutical and technology companies. However, Asia-Pacific is projected to witness the fastest growth during the forecast period, fueled by increasing healthcare spending and the rising adoption of advanced analytics technologies in emerging economies. Competitive pressures are intense, with established players like Accenture, IBM, and Oracle vying with specialized analytics providers and cloud giants like Amazon and Microsoft. The market’s success depends on navigating regulatory hurdles, data privacy concerns, and the need for robust data integration capabilities. The competitive landscape is characterized by a mix of established technology companies offering comprehensive solutions and specialized firms focusing on niche applications within the life sciences sector. Strategic partnerships and acquisitions are becoming increasingly prevalent as companies seek to expand their market reach and technological capabilities. Industry risks include the need for significant investments in data infrastructure, the complexity of integrating diverse data sources, and the ongoing challenge of ensuring data security and compliance with stringent regulations like GDPR and HIPAA. Companies are responding by developing sophisticated algorithms, improving user interfaces, and offering comprehensive support and training services to address these challenges and maintain a strong competitive position. The market is expected to continue its upward trajectory, driven by sustained innovation and the increasing importance of data-driven decision-making in the life sciences industry. The long-term forecast indicates continued strong growth, with the market expanding significantly over the next decade.

West is a trusted partner to the world's top pharmaceutical and biotechnology companies, working together to improve patient health. Their company background emphasizes the importance of their designs and products, which nurture a culture of philanthropy and community involvement.

The company provides various solutions, including vial containment, prefilled syringe components, self-injection technologies, cartridge systems, and quality enhancements. These solutions promote the efficiency, reliability, and safety of the world's pharmaceutical drug supply.

West also emphasizes the importance of culture, stating that nurturing a culture of philanthropy and community involvement is one of the defining characteristicsn

Snapshot img

The blue biotechnology market share should rise by USD 3.58 billion from 2021 to 2025 at a CAGR of 7.15%.

This blue biotechnology market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by application (pharmaceuticals, F&B, and others) and geography (North America, Europe, Asia, and ROW). The blue biotechnology market report also offers information on several market vendors, including AKER BIOMARINE AS, Archer Daniels Midland Co., BASF SE, Bawa Fishmeal and Oil Co., CP Kelco US Inc., Cyanotech Corp., Glyco Mar, KD Pharma Group SA, Marshall Marine Products, and Sea Run Holdings Inc. among others.

What will the Blue Biotechnology Market Size be in 2021?

To Unlock the Blue Biotechnology Market Size for 2021 and Other Important Statistics, Download the Free Report Sample!

Blue Biotechnology Market: Key Drivers and Trends

The increasing cancer incidence rates driving the demand for unconventional drugs is notably driving the blue biotechnology market growth, although factors such as increasing level of marine pollution may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the blue biotechnology market. The holistic analysis of the drivers will help in predicting end goals and refining marketing strategies to gain a competitive edge.

This blue biotechnology market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Blue Biotechnology Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

AKER BIOMARINE AS
Archer Daniels Midland Co.
BASF SE
Bawa Fishmeal and Oil Co.
CP Kelco US Inc.
Cyanotech Corp.
Glyco Mar
 KD Pharma Group SA
Marshall Marine Products
Sea Run Holdings Inc.

The vendor landscape of the blue biotechnology market entails successful business strategies deployed by the vendors. The blue biotechnology market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Download a free sample of the blue biotechnology market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Blue Biotechnology Market?

For more insights on the market share of various regions Request for a FREE sample now!

35% of the market’s growth will originate from North America during the forecast period. The US is the key market for blue biotechnology market in North America.

The report offers an up-to-date analysis of the geographical composition of the market. North America has been recording significant growth rate and is expected to offer several growth opportunities to market vendors during the forecast period. Increasing use of blue biotechnology for producing molecular probes will facilitate the blue biotechnology market growth in North America over the forecast period. The report offers an up-to-date analysis of the geographical composition of the market, competitive intelligence, and regional opportunities in store for vendors.

What are the Revenue-generating Application Segments in the Blue Biotechnology Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The blue biotechnology market share growth by the pharmaceuticals segment has been significant. This report provides insights on the impact of the unprecedented outbreak of COVID-19 on market segments. Through these insights, you can safely deduce transformation patterns in consumer behavior, which is crucial to gauge segment-wise revenue growth during 2021-2025 and embrace technologies to improve business efficiency.

This report provides an accurate prediction of the contribution of all the segments to the growth of the blue biotechnology market size. Furthermore, our analysts have indicated actionable market insights on post COVID-19 impact on each segment, which is crucial to predict change in consumer demand.

    Blue Biotechnology Market Scope




    Report Coverage


    Details




    Page number


    120




    Base year

The Clinical Data Management (CDM) and Statistical Analysis market is experiencing robust growth, driven by the increasing volume of clinical trial data generated by the burgeoning pharmaceutical and biotechnology industries. The market's complexity is amplified by the stringent regulatory requirements surrounding data integrity and analysis in clinical trials. While precise figures for market size and CAGR are not provided, based on industry reports and observable trends, a reasonable estimation would place the 2025 market size at approximately $15 billion, with a projected Compound Annual Growth Rate (CAGR) of 8% from 2025 to 2033. This growth is fueled by several key factors, including the rising adoption of electronic data capture (EDC) systems, the increasing demand for advanced statistical analysis techniques, and the growing outsourcing of CDM and statistical analysis services by pharmaceutical and biotech companies. This outsourcing trend allows companies to focus on core competencies while leveraging the expertise of specialized service providers. The market also witnesses significant investments in innovative technologies like artificial intelligence (AI) and machine learning (ML) for data processing and analysis, streamlining workflows and improving the efficiency of clinical trials. Despite this positive outlook, the market faces challenges. The high cost of implementing and maintaining advanced CDM systems can be a barrier to entry for smaller companies. Furthermore, the need for highly skilled professionals in biostatistics and data management creates a talent shortage that impacts service delivery and overall market expansion. However, the ongoing technological advancements and the increasing demand for efficient clinical trials are expected to outweigh these restraints, ensuring continued growth in the coming years. The market is segmented across various service providers, including large multinational CROs like IQVIA and Charles River Laboratories, as well as specialized smaller firms catering to niche markets. Geographic variations in regulatory landscapes and adoption rates also play a significant role in shaping the market's dynamics.

The Genetic Data Analysis Software market is a rapidly evolving sector that plays a pivotal role in the field of genomics, biotechnology, and personalized medicine. As the importance of genetic data in research and clinical settings grows, the demand for sophisticated software solutions that can handle the complexit

According to the Fortune China 500 ranking in 2024, Guangzhou Pharmaceutical ranked first among Chinese biotech and pharmaceutical companies, with an annual revenue of about ************* U.S. dollars in 2023. Chongqing Zhifei Biological Products was the second placeholder with almost *********** U.S. dollars in annual revenue. The ranking is based on total revenue in 2023 and was released in July 2024. Brief overview of the industry China was one of the pioneers of the medical and healthcare industry in the Asia-Pacific region, especially in the fields of pharmaceuticals and biotechnology. The Chinese pharmaceuticals industry had registered promising growth in recent years, mainly due to favourable market regulation policies which had broadened the market access of patented drugs. The leading pharmaceutical manufacturer, Shanghai Pharmaceuticals, registered significant growth in revenue in the last decade. Its rise has been aided by the faster approval process of new drugs, overseas market expansion and a collective industry movement towards innovative products. The role of traditional Chinese medicine (TCM) With over 3000 years of history, the Chinese tradition of using animal and herbal extracts for treatment is gaining gradual popularity among its western counterparts. Guangzhou Baiyunshan Pharmaceuticals, Yunnan Baiyao Group, and Beijing Tong Reng Tang are the prominent TCM manufacturers with considerable gross profits. The traditional Chinese medicine industry has received progressive assistance from government initiatives to improve industry standards and efficiency in the production of traditional medicine. In the COVID-19 pandemic, TCM also played an important role as a measure to boost public immunity.

The biotechnology and pharmaceutical sector has grown in importance over the past few decades and the value of M&A deals increased accordingly. In 2023, the value of M&A transactions in this sector amounted to a total of approximately *** billion U.S. dollars. However, this is a far cry from the peak of *** billion U.S. dollars in 2014.

Background Pairs of related individuals are widely used in linkage analysis. Most of the tests for linkage analysis are based on statistics associated with identity by descent (IBD) data. The current biotechnology provides data on very densely packed loci, and therefore, it may provide almost continuous IBD data for pairs of closely related individuals. Therefore, the distribution theory for statistics on continuous IBD data is of interest. In particular, distributional results which allow the evaluation of p-values for relevant tests are of importance. Results A technology is provided for numerical evaluation, with any given accuracy, of the cumulative probabilities of some statistics on continuous genome data for pairs of closely related individuals. In the case of a pair of full-sibs, the following statistics are considered: (i) the proportion of genome with 2 (at least 1) haplotypes shared identical-by-descent (IBD) on a chromosomal segment, (ii) the number of distinct pieces (subsegments) of a chromosomal segment, on each of which exactly 2 (at least 1) haplotypes are shared IBD. The natural counterparts of these statistics for the other relationships are also considered. Relevant Maple codes are provided for a rapid evaluation of the cumulative probabilities of such statistics. The genomic continuum model, with Haldane's model for the crossover process, is assumed. Conclusions A technology, together with relevant software codes for its automated implementation, are provided for exact evaluation of the distributions of relevant statistics associated with continuous genome data on closely related individuals.

Snapshot img

US Biotechnology Market Size 2025-2029

The US biotechnology market size is forecast to increase by USD 295.3 billion at a CAGR of 11.5% between 2024 and 2029.

The biotechnology market is experiencing significant growth due to several key factors. The rising prevalence of chronic and rare diseases is driving market demand, as biotechnology offers innovative solutions for diagnosing, treating, and managing these conditions. Additionally, the integration of artificial intelligence (AI) and machine learning technologies is revolutionizing the industry, enabling more accurate diagnoses and personalized treatments. However, regulatory hurdles pose a challenge to market growth. Strict regulations and lengthy approval processes can hinder the development and commercialization of new biotechnology products. Despite these challenges, the future of the biotechnology market looks promising, with continued innovation and advancements in technology expected to drive growth.

What will be the Size of the market During the Forecast Period?

Request Free Sample

The biotechnology market encompasses a broad range of technologies and applications, including regeneration technologies for neurological disorders such as age-related macular degeneration and Alzheimer's disease, as well as clinical successes in gene therapy for cancer and genetic abnormalities. Agricultural biotechnology also plays a significant role, with advancements in tissue culture technology leading to the development of pest-free banana varieties and insect-resistant seeds. Tissue engineering and cell therapy are other key areas of focus, with clinical trials underway for chronic diseases like arthritis, type 2 diabetes, and TB.



The regulatory framework for biotechnology is evolving, with approvals for personalized medicine and cell-based assays driving investments in this field. Research activities span from biochemistry and chromatography to proteomics and PCR, with funding opportunities available from both public and private sources. Miniaturized portable instruments and clinical diagnostic tests are also gaining traction, as the industry continues to innovate and address the challenges of clinical studies and regulatory approval processes.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Biologics
  Therapeutics
  Diagnostics
  Industrial biotechnology
  Others


Type

  Red biotechnology
  White biotechnology
  Green biotechnology
  Grey biotechnology
  Others


Geography

  US

By Product Insights

The biologics segment is estimated to witness significant growth during the forecast period.

The biotechnology market is primarily driven by the segment of biologics, which comprises drugs derived from or containing components of living organisms. This category includes monoclonal antibodies, vaccines, hormones, blood products, and gene therapies. Biologics have revolutionized modern medicine by providing targeted treatments for conditions such as cancer, autoimmune diseases, and genetic disorders. Their higher efficacy and specificity compared to traditional small-molecule drugs have led to significant growth in this segment.

Furthermore, substantial investments in manufacturing and research facilities have further bolstered the biologics market. Biotechnology advancements in areas like gene editing technologies, stem cell therapy, and disease prevention strategies have fueled innovation in medical biotechnology. In agricultural biotechnology, biotech solutions are addressing food security challenges. Clinical trial design and biopharmaceutical development continue to be critical areas of focus for market expansion.

Get a glance at the market report of share of various segments Request Free Sample

Market Dynamics

Our US Biotechnology Market researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in the adoption of the US Biotechnology Market?

Rising prevalence of chronic and rare diseases is the key driver of the market.

The US biotechnology market is experiencing significant growth due to the increasing prevalence of chronic and rare diseases. Approximately 130 million Americans were reported to have at least one major chronic condition in 2023, including heart disease, cancer, diabetes, obesity, and hypertension. Biotechnology offers innovative solutions for managing and treating these conditions through precision medicine, genetic engineering applications, and biomedical engineering. In the field of ag

The size of the Computational Biology Industry market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 13.33% during the forecast period. The computational biology industry is booming, driven by the growth in volumes of biological data generated by advancing genomics, proteomics, and systems biology. It involves an interdisciplinary approach that links biology, computer science, and mathematics to analyze complicated biological systems and processes-deemed indispensable for drug discovery, personalized medicine, and agricultural biotechnology. The rising incidence of chronic diseases necessitates targeted therapies and precise diagnostics, thereby becoming a key driver for market growth. The tools of computational biology, which include bioinformatics software, machine learning algorithms, and modeling simulations, enable the extraction of meaningful insights from vast datasets, accelerating the pace of scientific discovery. Technological advancements are further enhancing the functionality of computational biology. The way biological data is interpreted in terms of analysis is undergoing a fundamental shift with AI and machine learning being increasingly integrated in data analysis. Moreover, cloud computing makes it easy for researchers to share data as well as collaborate, making innovation in this field flourish. Geographical center, North America, strong existence of research institutions, biotechnology firms, and investments by funding in life sciences research. Asia-Pacific is emerging, with increased investments in the healthcare and biotechnology sectors and growing importance of personalized medicine. Essentially, the overall industry of computational biology would seem to have excellent chances for sustained expansion based on the further advancing nature of technology, be it a need to gain a clearer sense of incredible data sizes or the overall emphasis to expand focus around precision health solutions. Biological science continually advancing, through computation will unlock new sights, it will be driving an innovation engine across every single domain of healthcare delivery services. Recent developments include: February 2023: The Centre for Development of Advanced Computing (C-DAC) launched two software tools critical for research in life sciences. Integrated Computing Environment, one of the products, is an indigenous cloud-based genomics computational facility for bioinformatics that integrates ICE-cube, a hardware infrastructure, and ICE flakes. This software will help securely store and analyze petascale to exascale genomics data., January 2023: Insilico Medicine, a clinical-stage, end-to-end artificial intelligence (AI)-driven drug discovery company, launched the 6th generation Intelligent Robotics Lab to accelerate its AI-driven drug discovery. The fully automated AI-powered robotics laboratory performs target discovery, compound screening, precision medicine development, and translational research.. Key drivers for this market are: Increase in Bioinformatics Research, Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics; Growth of Drug Designing and Disease Modeling. Potential restraints include: Lack of Trained Professionals. Notable trends are: Industry and Commercials Sub-segment is Expected to hold its Highest Market Share in the End User Segment.

Snapshot img

Biotech Market Size 2025-2029

The biotech market size is forecast to increase by USD 805.6 billion at a CAGR of 12.4% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing innovation and investment from market companies. These companies are expanding their research and development efforts to bring new products and technologies to market, addressing unmet medical needs and advancing scientific discoveries. However, this growth comes with challenges, primarily regulatory compliance. Stringent regulations governing the biotech industry ensure the safety and efficacy of products, but they also add costs and complexity to the development process. Biologics, comprised of monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies, are derived from living organisms and cater to the treatment of numerous diseases, such as cancer, autoimmune disorders, and genetic conditions. Navigating these regulations requires the regulatory landscape and strategic planning.
For companies seeking to capitalize on market opportunities and navigate challenges effectively, it is essential to stay informed of the latest regulatory trends and best practices. Additionally, collaboration with regulatory agencies and industry experts can help streamline the development process and bring products to market more efficiently. Overall, the market presents significant opportunities for growth, but companies must be prepared to navigate regulatory complexities and invest in innovation to stay competitive.

What will be the Size of the Biotech Market during the forecast period?

Request Free Sample

The market encompasses a dynamic and innovative industry focused on advancing biological systems through engineering, gene therapies, and tissue culturing. This sector is driving progress in various areas, including medicine, environmental sustainability, and agriculture. Notable applications include the development of treatments for conditions such as HIV, diabetes, obesity, neurological disorders, and transfyretin amyloidosis. Significant investments continue to fuel market growth, with innovative companies spearheading clinical success in areas like personalized medicine and regeneration technologies. Biotech is also making strides in the production of genetically modified crops, leading to improved plant varieties and increased agricultural efficiency. Government support and approval processes are crucial components of the market's growth trajectory.
Technological advancements, such as molecular breeding and cloning, are revolutionizing the way we approach challenges in healthcare and agriculture. The biotech industry's positive outcomes extend beyond the conventional plan, with potential solutions for societal issues like malaria and sedentary lifestyle-related diseases. Market revenue is expected to grow substantially as biotech continues to deliver breakthroughs in medicine, bio-pharmaceuticals, and bio-agriculture. The future of this sector is bright, as it continues to push the boundaries of science and technology to address some of the world's most pressing challenges.

How is this Biotech Industry segmented?

The biotech industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Biologics
  Therapeutics
  Diagnostics
  Industrial biotechnology
  Others


Type

  Red biotechnology
  White biotechnology
  Green biotechnology
  Grey biotechnology
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Sweden
    Switzerland
    UK


  Asia
  Rest of World (ROW)

By Product Insights

The biologics segment is estimated to witness significant growth during the forecast period. The market encompasses a range of product categories, with biologics emerging as a key and expanding segment. In August 2023, Novartis finalized its acquisition of Chinook Therapeutics, Inc., a Seattle, WA-based biopharmaceutical company specializing in precision medicines for kidney diseases. Valued at up to USD 3.5 billion, this acquisition underscores the strategic significance of biologics within the global biotech sector. Biotechnology advancements in areas like gene editing, proteomics, and genomics continue to fuel innovation in disease treatment and prevention.

Biotech startups and established biopharma companies alike invest heavily in research and development, driving medical breakthroughs and healthcare solutions. The biotech industry's focus on patient care, disease management, and pharmaceutical innovation is transforming healthcare trends and improving health outcomes. Biotechnology education, policy, and regulation play crucial roles in fostering a sustainable and ethical industry.

Get a

Unravelling the pattern of traditional plant usages in a society is necessary to inform interventions for biodiversity conservation. In the present study, we documented traditional knowledge of plant usages and analysed the pattern of culturally important plants along a phylogeny of South Africa’s medicinal plants. Data were collected through interviews, field visits and group discussions, and cultural importance was assessed using two metrics: use value (UV_s) and quality use value of species (QUV_s). K statistic was used to assess how UV_s and QUV_s values are distributed on a phylogeny. Overall, 50 medicinal plant species in 35 botanical families were reported. Fabaceae and Celastraceae contain more medicinal species than any other family, perhaps because of a wider distribution in the study area. Although there was no evidence that knowledge of medicinal uses varies significantly according to informant status, sex, ethnic group and age category, or residence time of the informant in the study area, traditional healers show a wider range of medicinal knowledge than any other informants. Culturally important plants are not significantly clustered on the phylogeny, suggesting a priori a limited value of phylogeny in identifying culturally valuable plants. However, this potential limitation could be driven by the local focus of the present study. We call for further investigations at a broader scale to establish potential phylogenetic signals in plant cultural importance.

This round of Euro-Barometer surveys queried respondents on standard Euro-Barometer measures such as public awareness of and attitudes toward the Common Market and the European Community (EC), and also focused on biotechnology, genetic engineering, and energy policies. Respondents were questioned about their opinions regarding the application of biotechnology and genetic engineering to humans, animals, and plants. Opinions were also gathered on the need for ethical rules for the application of biotechnology, the use of biotechnology for changing hereditary characteristics, the need to balance animal and human welfare, the effectiveness of traditional breeding methods compared to genetic engineering, protection of the environment, and the influence of people and groups on the development of biotechnology. Energy-related topics covered the efficiency of public bodies in acting to conserve energy, the responsibility for energy investment decisions, the importance of stable energy prices, reliable energy supplies, and low pollution risks, and proposals to increase taxes on energy consumption and on packaging that pollutes the environment. In addition, respondents were queried about their satisfaction with their current housing, the area in which they lived, and the travel time from home to work. Respondent willingness to move in order to find or change jobs and their reasons for moving or not moving were also probed. On EC matters, respondents were asked about their satisfaction with and expectations for product purchases in other EC countries, whether national institutions of the relevant EC country or EC institutions were better able to solve potential buying or selling problems with other EC member states, and whether the respondent lived within 30 kilometres of another EC country. Demographic and other background information was gathered on number of people residing in the home, size of locality, home ownership, trade union membership, region of residence, and occupation of the head of household, as well as the respondent's age, sex, marital status, education, occupation, work sector, religiosity, subjective social class, left-right political self-placement, and opinion leadership.

This round of Eurobarometer surveys queried respondents on standard Eurobarometer measures such as public awareness of and attitudes toward the European Union (EU), and also focused on modern biotechnology, the common European currency, and privacy on computer networks. With respect to modern biotechnology issues, respondents were asked for their opinions regarding which organizations should regulate modern biotechnology, and the likelihood that in the next 20 years biotechnology would lead to events such as reducing environmental pollution and world hunger, creating dangerous new diseases, solving more crimes through genetic fingerprinting, curing genetic diseases, and producing designer babies. Computer network privacy issues covered respondents' worries about leaving "electronic tracks" of personal identifying information when using computer network services and concerns about the use of information collected from network services for advertising, or by shops, insurance companies, or public bodies. Other data protection questions probed for respondents' willingness to use new communication technologies and electronic services considering that someone else might use their personal information, awareness and concern about using a means of payment on networks that might leave tracks, awareness of laws that protect privacy, the importance of the EU trying to protect personal information, and the importance of worldwide privacy of personal information. Also covered were respondent interest in on-screen computer or television network technologies and in the capabilities these technologies provide, such as getting a medical opinion on a health issue, an on-line guided tour of a museum, receiving instant access to newspapers, taking part in a training program, making it easier to look for a job, taking part in discussion groups, receiving and sending electronic mail, managing bank and financial accounts, and organizing a trip. Common European currency items included whether respondents were for or against one European currency in all member states and why, how well-informed they felt about the common European currency, their knowledge of the conditions member countries must meet in order to join the European Economic and Monetary Union, when notes and coins in the European currency would be introduced, their own country's ability to take part in the Single European Currency in 1999, the consequences for not participating, and what the rate of introduction should be for the common European currency. Questions asked only in Sweden concerned attitudes toward expanding or reducing nuclear power, the respondent's three favorite activities, and highest level of education completed. Demographic items include age, gender, marital status, household size, monthly income, age when stopped full-time education, and occupation. (Source: downloaded from ICPSR 7/13/10)

Please Note: This dataset is part of the historical CISER Data Archive Collection and is also available at ICPSR -- https://doi.org/10.3886/ICPSR06940.v1. We highly recommend using the ICPSR version as they made this dataset available in multiple data formats.

Einstellung zur Biotechnologie, zur Informationstechnologieund zum Datenschutz. Einstellung zum EURO. Themen der nächstennationalen Wahlen. Themen: Staatsangehörigkeit (Mehrfachnennungen möglich);eigene Meinungsführerschaft und Häufigkeit politischerDiskussionen; allgemeine Einstellung zur Mitgliedschaft deseigenen Landes in der EU; Vorteilhaftigkeit dieserMitgliedschaft. 1. Biotechnologie: Erwartete Verbesserungen bzw.Verschlechterungen durch die Auswirkungen neuer Technologienwie Solarenergie, Informationstechnologie, Biotechnologie,Telekommunikation, neue Materialien und Weltraumforschung;Assoziationen zur Biotechnologie; Kenntnistest in modernerBiotechnologie und Gentechnologie (Skala); Einschätzungbestimmter Eigenschaften und Fähigkeiten des Menschen alsprimär vererbbar oder durch Erziehung und Lebensumständebedingt (Skala); Einschätzung von Nutzen und Risiken für dieGesellschaft sowie der moralischen Vertretbarkeit undFörderungswürdigkeit von Biotechnologie zur Herstellung vonLebensmitteln, Genübertragung auf andere Pflanzenarten,Übertragung menschlicher Gene auf Bakterien zur Herstellungvon Medikamenten, zur Züchtung gentechnisch veränderter Tierein Laborversuchen, zur Übertragung menschlicher Gene aufTiere, zur Organtransplantation und zur Durchführunggenetischer Tests beim Menschen, um Krankheiten identifizierenzu können; Einstellung zur Biotechnologie (Skala); präferierteInstitutionen und Organisationen zur Kontrolle derbiotechnologischen Forschung; erwartete Auswirkungen durch diemoderne Biotechnologie in den nächsten 20 Jahren;vertrauenswürdige Informationsquellen zur Biotechnologie;allgemeine Einschätzung der Wichtigkeit modernerBiotechnologie (Skalometer); genutzte Informationsquellen überBiotechnologie; Häufigkeit von Gesprächen über Biotechnologie. 2. Wahlkampf: Wichtigste politische Themen für den nächstennationalen Wahlkampf; Nutzung von Zeitungen und Zeitschriften. 3. Währung: Einstellung zu einer europäischen Währung undwichtigste Gründe für bzw. gegen eine europäische Währung;Selbsteinschätzung des Informationsgrades über die neueeuropäische Währung; Kenntnisse über die Beitrittsbedingungenzur Währungsunion (Test); präferiertes Einführungsdatum fürden EURO; Einschätzung, ob das Land des Befragten in derersten oder zweiten Einführungsrunde die Bedingungen zurWährungsunion erfüllen wird; Erwartung positiver odernegativer Folgen im Falle einer Nichteinführung dereuropäischen Währung für das Land des Befragten; Kenntnisseüber den EURO (Test); erwartete Auswirkungen einer gemeinsamenWährung (Skala); Präferenz für ausgedehntenEinführungszeitraum für das neue Geld; präferierte Zeiträumefür eine duale Preisauszeichnung in Geschäften, beiRechnungen, Kontoauszügen und Gehaltsabrechnungen vorEinführung der Umstellung sowie nach dem Einführungsdatum;wichtigste Befürchtungen bei der Währungsumstellung;präferierte Institutionen und Themen für die Durchführungeiner Informationskampagne im Zusammenhang mit derWährungsumstellung; Beurteilung ausgewählter Werbeslogans zurWährungsumstellung bezüglich ihres Informationsgehalts, ihrerVerständlichkeit, ihrer Überzeugungskraft und ihresRealitätsbezugs; präferierte Distributionskanäle fürInformationen zur europäischen Währung. 4. Informationstechnologie und Datenschutz: Interesse aneiner Internetnutzung, Computer- oder Videotextnutzung überdas Fernsehgerät, um den Zugang zu verschiedenenDienstleistungen zu gewinnen, wie Behördenkontakte von zuHause aus, Zeitungsnutzung, Produktinformationen, Teilnahme anGesprächsrunden und Foren, E-mail-Versand, Kontenverwaltung,Buchung von Reisen und Nutzung virtueller Realitäten;Besorgnis, in Netzwerken elektronische Spuren zu hinterlassen;Ausmaß der Besorgnis über die Weitergabe persönlicher Daten anWirtschaftsunternehmen; Nutzung neuerKommunikationstechnologien in Abhängigkeit von derDatenschutzfrage; Abhängigkeit der eigenen Bereitschaft zurelektronischen Zahlung vom Datenschutz; Kenntnis deseuropäischen Datenschutzgesetzes; Wichtigkeit desDatenschutzes auf europäischer Ebene sowie auf Weltebene;Selbsteinschätzung auf einem Links-Rechts-Kontinuum. Demographie; zuständige Person für Einkauf undHaushaltsführung; Selbsteinstufung als religiös oderatheistisch; Kirchgangshäufigkeit. Zusätzlich verkodet wurden: Interviewdatum; Interviewbeginn;Interviewdauer: Anzahl der anwesenden Personen beim Interview;Kooperationsbereitschaft des Befragten; Ortsgröße. Attitude to biotechnology, information technology and data protection.Attitude to the EURO. Topics of the next national elections. Topics:nationality (multiple responses possible); personal opinion leadershipand frequency of political discussions; general attitude to membershipof one´s country in the EU; advantageousness of this membership. 1. Biotechnology: expected improvements or worsening through theeffects of new technologies such as solar energy, informationtechnology, biotechnology, telecommunication, new materials and spaceresearch; associations with biotechnology; knowledge test in modernbiotechnology and gene technology (scale); assessment of certaincharacteristics and abilities of humans as primarily inheritable or dueto education and circumstances (scale); assessment of benefits andrisks for society as well as the moral defensibility and degree towhich deserving of support of biotechnology in production of foods,gene transfer to other types of plants, transfer of human genes tobacteria to produce medications, to breed gene-technologically alteredanimals in laboratory experiments, to transfer human genes to animals,for organ transplantation and to conduct genetic tests on people to beable to identify illnesses; attitude to biotechnology (scale);preferred institutions and organizations to supervise biotechnologicalresearch; expected effects from modern biotechnology in the next 20years; trustworthy sources of information on biotechnology; generalassessment of importance of modern biotechnology (scale); sources ofinformation used on biotechnology; frequency of conversations aboutbiotechnology. 2. Election campaign: most important political topics for the nextnational election campaign; use of newspapers and magazines. 3. Currency: attitude to a European currency and most importantreasons for or against a European currency; self-assessment of degreeof information about the new European currency; knowledge aboutconditions for joining the currency union (test); preferredintroduction date for the EURO; assessment whether the country ofrespondent will fulfill the conditions for the currency union in firstor second introduction round; expectation of positive or negativeconsequences for the country of respondent in case of non-introductionof the European currency; knowledge about the EURO (test); expectedeffects of a common currency (scale); preference for extendedintroduction time interval for the new money; preferred time intervalsfor dual pricing in stores, on bills, bank account statements andsalary statements before introduction of the conversion as well asafter the introduction date; most important concerns in currencyconversion; preferred institutions and topics for conducting aninformation campaign in connection with currency conversion; judgementon selected advertising slogans on currency conversion regarding theirinformation content, their understandability, their persuasiveness andtheir relation to reality; preferred distribution channels forinformation on the European currency. 4. Information technology and data protection: interest in use of theInternet, computer or teletext use via the television set, in order toobtain access to various services such as contact with authorities fromat home, newspaper use, product information, participation inconversation rounds and forums, sending e-mail, bank accountmanagement, booking travel and use of virtual realities; concern aboutleaving electronic traces behind in networks; extent of concern aboutpassing on personal data to private businesses; use of newcommunication technologies depending on the data protection question;dependence of one´s own readiness for electronic payment on dataprotection; knowledge about the European data protection law;importance of data protection on European level as well as on worldlevel; self-assessment on a left-right continuum. Demography: person responsible for shopping and housekeeping; self-classification as religious or atheist; frequency of church attendance. Also encoded were: date of interview; start of interview; length of interview;number of persons present during interview; willingness of respondentto cooperate; city size.

An intense suppression of T cell proliferation to mitogens and to antigens is observed in a large number of parasitic infections. The impairment of T cell proliferation also occurred during the acute phase of Chagas' disease, caused by the intracellular protozoan parasite Trypanosoma cruzi. A wealth of evidence has accumulated that illustrates the ability of T. cruzi released molecules to influence directly a variety of diverse immunological functions. In this paper, we review the data concerning the immunoregulatory effects of T. cruzi Tc24 (a B cell activator antigen) and Tc52 (an immunosuppressive protein) released molecules on the host immune system. The gene targeting approach developed to further explore the biological function(s) of Tc52 molecule, revealed interesting unexpected functional properties. Indeed, in addition to its immunusuppressive activity a direct or indirect involvement of Tc52 gene product alone or in combination with other cellular components in T. cruzi differentiation control mechanisms have been evidenced. Moreover, targeted Tc52 replacement allowed the obtention of parasite mutants exhibiting low virulence in vitro and in vivo. Thus, the generation of a complete deficiency state of virulence factors by gene targeting should provide a means to assess the importance of these factors in the pathophysiological processes and disease progression. It is hoped that such approaches might allow rational design of tools to control T. cruzi infections.